Physician profile
Brian K Lang
NPI 1023072329
$2,422.91
in general payments reported to CMS, 2019-2025
22 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $32.37 · 2021: $14.99 · 2022: $89.27 · 2023: $16.05 · 2024: $817 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $431.67 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $292.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $280.83 | 2022-2025 | |
| Amgen INC. | $229.41 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $189.26 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.59 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Exact Sciences Corporation | $135.35 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $109.90 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $100.79 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.65 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $78.42 | 2024-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $60.83 | 2024-2025 | Watchman Flx |
| Recor Medical INC | $58.65 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abbott Laboratories | $35.29 | 2024-2025 | Proclaim, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $32.78 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30.00 | 2021-2025 | |
| Medtronic, INC. | $23.84 | 2025 | Inceptiv |
| Esperion Therapeutics, INC. | $17.79 | 2025 | Nexletol |
| Allergan, INC. | $16.44 | 2019 | |
| Dexcom, INC. | $15.62 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $15.02 | 2022 | |
| Astellas Pharma US INC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.